http://www.zibb.com/all/theme/cq/Compugen+Limited Zibb. The Global business search engine. en-US search@zibb.com (RB Search)Copyright (c) 2007 Reed Business Information. All rights reserved.Wed, 11 Nov 2009 01:00:17 GMTWed, 11 Nov 2009 01:00:17 GMT608831http://www.zibb.com/all/theme/cq/Compugen+Limited http://www.zibb.com/images/en/g_zibb_logo_beta.gif http://www.zibb.com/article/5660017/Compugen+Reports+Discovery+of+Genetic+Biomarker+for+Predisposition+to+Type+DiabetesCompugen has announced the discovery and experimental confirmation of a genetic biomarker, CGEN-40001 for predisposition to type 2 diabetes, the most common form of diabetes. In a release, the Company noted: This new biomarker was discovered using Compugen's GeneVa platform, which consists of an inhttp://www.zibb.com/article/5660017/Compugen+Reports+Discovery+of+Genetic+Biomarker+for+Predisposition+to+Type+DiabetesCompugen LimitedWed, 11 Nov 2009 01:00:17 GMThttp://www.rdmag.com/News/FeedsAP/2009/10/energy-service-benchmarking-puts-compugen-among-global-se/Service Benchmarking Puts Compugen Among Global Service Quality Leaders Past Five Yearshttp://www.rdmag.com/News/FeedsAP/2009/10/energy-service-benchmarking-puts-compugen-among-global-se/Compugen LimitedWed, 28 Oct 2009 19:25:54 GMThttp://www.biospace.com/news_story.aspx?StoryID=158868&full=1TEL AVIV, Israel--(BUSINESS WIRE)--Compugen Ltd. announced today that they have signed a collaboration agreement with Bayer Schering Pharma AG, Germany (“Bayer”) covering the further evaluation of a Compugen discovered tumor target and its splice variants.http://www.biospace.com/news_story.aspx?StoryID=158868&full=1Compugen LimitedTue, 13 Oct 2009 12:00:00 GMThttp://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=8370Compugen Ltd. (NASDAQ:CGEN) announced today that they have signed a collaboration agreement with Bayer Schering Pharma AG, Germany (“Bayerâ€) covering the further evaluation of a Compugen discovered tumor target and itshttp://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=8370Compugen LimitedTue, 13 Oct 2009 01:00:00 GMThttp://www.dcnonl.com/rss/id35436IT firm Compugen has broken ground on a new 120,000 square-foot national headquarters which will include a call centre, technology lab and warehouse.http://www.dcnonl.com/rss/id35436Compugen LimitedThu, 24 Sep 2009 10:33:16 GMThttp://www.newratings.com/en/main/company_headline.m?id=1944871NEW YORK, July 29 (newratings.com) - Analysts at Cantor Fitzgerald initiate coverage of Compugen Ltd (ticker: CGEN) with a "buy" rating. The target price is set to $6.50. [more]http://www.newratings.com/en/main/company_headline.m?id=1944871Compugen LimitedWed, 29 Jul 2009 18:40:56 GMThttp://finance.yahoo.com/news/Compugen-Reports-Sale-of-a-bw-458591102.html?x=0&.v=1TEL AVIV, Israel--(BUSINESS WIRE)--Compugen Ltd. (NASDAQ:CGEN - News) announced today that it has received approximately $3.6 million from thehttp://finance.yahoo.com/news/Compugen-Reports-Sale-of-a-bw-458591102.html?x=0&.v=1Compugen LimitedTue, 30 Jun 2009 10:00:00 GMThttp://www.genengnews.com/news/bnitem.aspx?name=56961752Money covers anti-inflammatory, cancer, and cardiovascular programs to assess novel peptides and proteins in those disorders.http://www.genengnews.com/news/bnitem.aspx?name=56961752Compugen LimitedWed, 24 Jun 2009 00:00:00 GMThttp://soa.sys-con.com/node/799317One of my favorite sayings is, "If you don't know where you're going, any direction will do." While in many cases people take that as license to do whatever they feel like, what it really means is that before you embark on a journey, you should plan your destination.http://soa.sys-con.com/node/799317Compugen LimitedTue, 06 Jan 2009 17:15:00 GMThttp://www.pharmaceutical-business-review.com/article_news.asp?guid=F0BEBF68-BC6D-44C4-B203-298EE90F3B26Compugen, a drug and diagnostic product candidate discovery company, has signed a collaboration agreement with Merck KGaA, acting for its pharmaceutical division Merck Serono, covering CGEN-855, a Compugen-discovered novel peptide targeting the FPRL1 G-protein coupled receptor.http://www.pharmaceutical-business-review.com/article_news.asp?guid=F0BEBF68-BC6D-44C4-B203-298EE90F3B26Compugen LimitedThu, 27 Nov 2008 14:18:00 GMThttp://www.contractpharma.com/news/2008/11/26/compugen%2c_merck_serono_enter_inflammatory_drug_pact__Compugen Ltd. has signed a collaboration agreement with Merck KGaA, a division of Merck Serono, for CGEN-855, Compugen's novel peptide targeting the FPRL1 G-protein coupled receptor (GPCR).http://www.contractpharma.com/news/2008/11/26/compugen%2c_merck_serono_enter_inflammatory_drug_pact__Compugen LimitedWed, 26 Nov 2008 13:45:00 GMThttp://wireless.sys-con.com/node/712087Mike Neil is general manager for virtualization strategy in the Windows Server Division at Microsoft Corp in Redmond, Wash. Mike is focused on the delivery of the Windows virtualization technology, including Windows Server 2008 Hyper-V, Microsoft Hyper-V Server and Virtual PC 2007.http://wireless.sys-con.com/node/712087Compugen LimitedThu, 16 Oct 2008 23:45:00 GMThttp://www.marketwire.com/press-release/Evogene-NASDAQ-CGEN-894045.htmlST. LOUIS, MO and REHOVOT, ISRAEL--(Marketwire - August 28, 2008) - Monsanto Company (NYSE: MON) and Evogene Ltd. (TASE: EVGN) have entered into a five-year research and development collaboration focused on identifying key plant genes related to yield, environmental stress and fertilizerhttp://www.marketwire.com/press-release/Evogene-NASDAQ-CGEN-894045.htmlCompugen LimitedThu, 28 Aug 2008 12:00:00 GMThttp://www.itbusiness.ca/it/client/en/home/news.asp?id=49084Google's business practice of retaining all the search queries of YouTube viewers puts users' data at risk, say privacy advocates.http://www.itbusiness.ca/it/client/en/home/news.asp?id=49084Compugen LimitedTue, 08 Jul 2008 18:14:36 GMThttp://www.prnewswire.com/cgi-bin/stories.pl?ACCT=109&STORY=/www/story/06-16-2008/0004832863&EDATE=Awards recognize partners' innovative use of Microsoft technology to exceed customer expectations and solve business problems. REDMOND, Wash., June 16 /PRNewswire-FirstCall/ -- Recognizing partners that delivered exemplary solutions to customers, Microsoft Corp.http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=109&STORY=/www/story/06-16-2008/0004832863&EDATE=Compugen LimitedMon, 16 Jun 2008 13:00:00 GMThttp://www.israelidiamond.co.il/English/News.aspx?boneId=918&objid=3382Israel Diamond Portal News Room Offers up-to-date Articles and Press Releases about the Diamond Industry, Diamond Technology, Markets and Tradinghttp://www.israelidiamond.co.il/English/News.aspx?boneId=918&objid=3382Compugen LimitedWed, 26 Mar 2008 08:06:00 GMThttp://blogs.msdn.com/enterprisesearch/archive/2008/03/02/delivering-on-the-promise-of-enterprise-search-for-the-masses.aspxToday, I ’ m very happy to write about our continued momentum in Enterprise Search! At the sold out SharePoint Conference here in Seattle, we're launching Search Server and Search Server Express to deliver on promise of enterprise search for the masses.http://blogs.msdn.com/enterprisesearch/archive/2008/03/02/delivering-on-the-promise-of-enterprise-search-for-the-masses.aspxCompugen LimitedMon, 03 Mar 2008 04:31:00 GMThttp://www.medicalnewstoday.com/articles/97284.phpCompugen Ltd. (NASDAQ:CGEN) announced positive in-vivo results for two novel peptide agonists of the MAS G-protein coupled receptor (GPCR), indicating cardio-protective effects and therapeutic pothttp://www.medicalnewstoday.com/articles/97284.phpCompugen LimitedThu, 14 Feb 2008 05:33:50 GMThttp://www.icis.com/Articles/2004/11/05/626042/compugen-premieres-biological-modeling.htmlTel Aviv, Israel-based Compugen Ltd. stands at the doorway of evolution in drug discovery. The company has developed a novel method to mathematically predict the existence of potential protein therapeutics, disease biomarkers and drug targets.http://www.icis.com/Articles/2004/11/05/626042/compugen-premieres-biological-modeling.htmlCompugen LimitedFri, 05 Nov 2004 18:50:30 GMThttp://www.dddmag.com/news-Biomarker-Candidate-For-Ovarian-Cancer-020309.aspxCompugen Ltd. announced the discovery and experimental verification of CGEN-327, a novel molecular biomarker candidate for the diagnosis of ovarian cancer.http://www.dddmag.com/news-Biomarker-Candidate-For-Ovarian-Cancer-020309.aspxCompugen Limitedhttp://www.tripwire.com/europe/news/press-releases/press-release.cfm?prid=286Richmond Hill, ON and Portland, OR - July 5, 2006 - Governments and businesses across Canada, faced with stricter regulations, are meeting their compliance obligations by implementing IT best practices. Tripwire Inc., the world leader in change auditing software, and Compugen Inc.http://www.tripwire.com/europe/news/press-releases/press-release.cfm?prid=286Compugen Limitedhttp://www.smartbrief.com/news/bio/companyData.jsp?companyId=2243&c=allaccesssppublished&page=2Business Wire | 53 days 10 hours 4 minutes ago Reportlinker.com announces that a new market research report related to the Diagnostic equipment industry is available in its catalogue.http://www.smartbrief.com/news/bio/companyData.jsp?companyId=2243&c=allaccesssppublished&page=2Compugen Limitedhttp://topics.nytimes.com/top/news/business/companies/compugen-ltd/index.htmlGet Home Delivery Log In Register Now Home Page My Times Today's Paper Video Most Popular Times Topics Business All NYT New York Times Business World U.S. N.Y. / Region Business Media & Advertising World Business Small Business Your Money DealBook Markets Research Mutual Funds My Portfolio Alertshttp://topics.nytimes.com/top/news/business/companies/compugen-ltd/index.htmlCompugen Limitedhttp://www.entrepreneur.com/tradejournals/article/print/183940716.htmlKotzer continued, "More recently, Compugen announced the successful completion of in vitro and in vivo validation tests for CGEN-50001, a drug that has been marketed for many years in Europe for central nervous system indications such as depression.http://www.entrepreneur.com/tradejournals/article/print/183940716.htmlCompugen Limitedhttp://www.holdrs.com/holdrs/main/index.asp?Action=Article&Description=&Image=&newsid={78180CF8-F99B-44BE-87C7-178CF42EBCAB}&symb=MKGA.Y&sid=2850234This peptide has demonstrated, in recently completed initial in vitro and in vivo studies, the potential to treat, among other indications, inflammatory diseases.http://www.holdrs.com/holdrs/main/index.asp?Action=Article&Description=&Image=&newsid={78180CF8-F99B-44BE-87C7-178CF42EBCAB}&symb=MKGA.Y&sid=2850234Compugen Limited